Cargando…
The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
Severe obesity is a strong risk factor for non-alcoholic fatty liver disease (NAFLD). Roux-en-Y gastric bypass (RYGB) surgery effectively induces weight loss, but few studies have described the long-term effects of RYGB on NAFLD-related fibrosis. Data from 220 patients with severe obesity operated b...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409952/ https://www.ncbi.nlm.nih.gov/pubmed/36013149 http://dx.doi.org/10.3390/jcm11164910 |
_version_ | 1784774976245596160 |
---|---|
author | Sandvik, Elfrid Christine Smith Aasarød, Kristin Matre Johnsen, Gjermund Hoff, Dag Arne Lihaug Kulseng, Bård Hyldmo, Åsne Ask Græslie, Hallvard Nymo, Siren Sandvik, Jorunn Fossmark, Reidar |
author_facet | Sandvik, Elfrid Christine Smith Aasarød, Kristin Matre Johnsen, Gjermund Hoff, Dag Arne Lihaug Kulseng, Bård Hyldmo, Åsne Ask Græslie, Hallvard Nymo, Siren Sandvik, Jorunn Fossmark, Reidar |
author_sort | Sandvik, Elfrid Christine Smith |
collection | PubMed |
description | Severe obesity is a strong risk factor for non-alcoholic fatty liver disease (NAFLD). Roux-en-Y gastric bypass (RYGB) surgery effectively induces weight loss, but few studies have described the long-term effects of RYGB on NAFLD-related fibrosis. Data from 220 patients with severe obesity operated by RYGB in Central Norway were analysed. Variables incorporated in NAFLD Fibrosis Score (NFS), Fibrosis-4 (FIB-4) index and anthropometric data were collected before surgery and a mean of 11.6 years postoperatively. FIB-4 > 1.3 or NFS > 0.675 were used as cut-off values for advanced fibrosis. Proportions with advanced fibrosis decreased from 24% to 14% assessed by FIB-4 and from 8.6% to 2.3% using NFS, with resolution rates of advanced fibrosis of 42% and 73%, respectively. The shift towards lower fibrosis categories was significant (NFS p < 0.0001; FIB-4 p = 0.002). NFS decreased from −1.32 (IQR −2.33–−0.39) to −1.71 (IQR −2.49–−0.95, p < 0.001) 11.6 years after surgery, whereas FIB-4 did not change: 0.81 (IQR 0.59–1.25) to 0.89 (IQR 0.69–1.16, p = 0.556). There were weak correlations between change in fibrosis scores and weight loss. In conclusion, the majority of patients with advanced fibrosis at baseline had improvement after 11.6 years. Factors associated with reduction in fibrosis were not identified. |
format | Online Article Text |
id | pubmed-9409952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94099522022-08-26 The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study Sandvik, Elfrid Christine Smith Aasarød, Kristin Matre Johnsen, Gjermund Hoff, Dag Arne Lihaug Kulseng, Bård Hyldmo, Åsne Ask Græslie, Hallvard Nymo, Siren Sandvik, Jorunn Fossmark, Reidar J Clin Med Article Severe obesity is a strong risk factor for non-alcoholic fatty liver disease (NAFLD). Roux-en-Y gastric bypass (RYGB) surgery effectively induces weight loss, but few studies have described the long-term effects of RYGB on NAFLD-related fibrosis. Data from 220 patients with severe obesity operated by RYGB in Central Norway were analysed. Variables incorporated in NAFLD Fibrosis Score (NFS), Fibrosis-4 (FIB-4) index and anthropometric data were collected before surgery and a mean of 11.6 years postoperatively. FIB-4 > 1.3 or NFS > 0.675 were used as cut-off values for advanced fibrosis. Proportions with advanced fibrosis decreased from 24% to 14% assessed by FIB-4 and from 8.6% to 2.3% using NFS, with resolution rates of advanced fibrosis of 42% and 73%, respectively. The shift towards lower fibrosis categories was significant (NFS p < 0.0001; FIB-4 p = 0.002). NFS decreased from −1.32 (IQR −2.33–−0.39) to −1.71 (IQR −2.49–−0.95, p < 0.001) 11.6 years after surgery, whereas FIB-4 did not change: 0.81 (IQR 0.59–1.25) to 0.89 (IQR 0.69–1.16, p = 0.556). There were weak correlations between change in fibrosis scores and weight loss. In conclusion, the majority of patients with advanced fibrosis at baseline had improvement after 11.6 years. Factors associated with reduction in fibrosis were not identified. MDPI 2022-08-21 /pmc/articles/PMC9409952/ /pubmed/36013149 http://dx.doi.org/10.3390/jcm11164910 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sandvik, Elfrid Christine Smith Aasarød, Kristin Matre Johnsen, Gjermund Hoff, Dag Arne Lihaug Kulseng, Bård Hyldmo, Åsne Ask Græslie, Hallvard Nymo, Siren Sandvik, Jorunn Fossmark, Reidar The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study |
title | The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study |
title_full | The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study |
title_fullStr | The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study |
title_full_unstemmed | The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study |
title_short | The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study |
title_sort | effect of roux-en-y gastric bypass on non-alcoholic fatty liver disease fibrosis assessed by fib-4 and nfs scores—an 11.6-year follow-up study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409952/ https://www.ncbi.nlm.nih.gov/pubmed/36013149 http://dx.doi.org/10.3390/jcm11164910 |
work_keys_str_mv | AT sandvikelfridchristinesmith theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT aasarødkristinmatre theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT johnsengjermund theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT hoffdagarnelihaug theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT kulsengbard theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT hyldmoasneask theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT græsliehallvard theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT nymosiren theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT sandvikjorunn theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT fossmarkreidar theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT sandvikelfridchristinesmith effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT aasarødkristinmatre effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT johnsengjermund effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT hoffdagarnelihaug effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT kulsengbard effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT hyldmoasneask effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT græsliehallvard effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT nymosiren effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT sandvikjorunn effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy AT fossmarkreidar effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy |